Table 1 Clinical characteristics of discovery and validation cohorts

# Of samples

95

54

Age (mean)

67.9 ± 8.1

67.1 ± 7.3

Gender, n (%)

 Female

51 (54%)

32 (59%)

 Male

41 (46%)

22 (41%)

Smoking status, n (%)

 Former

68 (73.9%)

34 (63%)

 Current

22 (23.9%)

16 (29.6%)

 Never

2 (2.2%)

4 (7.4%)

ECOG status, n (%)

 0

37 (39%)

20 (37.1%)

 1

41 (43.1%)

32 (60%)

 2

14 (14.7%)

1 (1.9%)

 3

3 (3.2%)

1 (1.9%)

Histology, n (%)

 Adenocarcinoma

77 (81%)

41 (76%)

 Squamous

14 (15%)

8 (14.8%)

 Other

4 (4%)

5 (9.2%)

EGFR status, n (%)

 Absent

75 (79%)

47 (87%)

 Present

3 (3.1%)

2  (3.7%)

 NT

17 (17.9%)

5 (9.3%)

PFS, n (%)

 6 months

51 (54%)

21 (38.9%)

 6 months

44 (46%)

33 (61.1%)

OS, n (%)

 6 months

78 (82%)

45 (83.3%)

 6 months

17 (18%)

9 (16.7%)